Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
A legfontosabb adatok
- Hol
- Houston (Egyesült Államok)A helyszín megnézése
Helyszínek itt: Egyesült Államok
- MD Anderson Cancer CenterHouston, Egyesült ÁllamokContact: Roy F. ChemalyToborzás még nem indult
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Azonosító
- NCT05234723
- A regiszteradat frissítve
- 2026. június 15.
- Eredeti leírás
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.A teljes eredeti leírásKevesebb
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
Bevonási feltételek: All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC; Ability to understand the purpose of the study and provide signed and dated informed consent.
Kizáró feltételek: Lack of the serological mismatch at transplantation; Lack of clinical and/or laboratory data regarding the type of CMV event; Lack of the type of SOT or HSCT; Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis.